Late-Breaking Science

Scientific Sessions 2017

Scientific Sessions: November 11–15

Resuscitation Science Symposium: November 11–13

Cardiovascular Nursing Clinical Symposium: November 13–14

Anaheim, California

Click on any Late Breaking session title below to see the lineup in the online Program Planner.

LBS.01. CABG and EP Peri-procedural Dilemmas

When: Sunday, November 12, 2017, 3:45 p.m. - 5:00 p.m.
Where: Main Event I (Hall D, Main Building)

  • TRICS III – An International Multicenter Randomized Trial of Transfusion Triggers in Cardiac Surgery
     
  • DACAB - Efficacy and Safety of Dual Acetylsalicylic Acid plus Ticagrelor or Ticagrelor Alone Antiplatelet Strategy after Coronary Artery Bypass Surgery at 12 months: Randomized Multicentre Trial
     
  • BRUISE CONTROL-2 - A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-coagulant at the time of Device Surgery
     
  • ABRIDGE J - Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

LBS.02. Late Breaking Science in Prevention

When: Monday, November 13, 2017, 9:00 a.m. - 10:15 a.m.
Where: Ballroom CD, 3rd Level (Main Building)

  • REAL-CAD - Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients with Stable Coronary Artery Disease
     
  • REVEAL - Effects of Anacetrapib on the Incidence of New-onset Diabetes Mellitus and on Vascular Events in People with Diabetes
     
  • FOURIER - Evolocumab and Outcomes in Patients with Peripheral Artery Disease
     
  • FOURIER - Clinical Benefit of Evolocumab in Patients with a History of MI: An Analysis from FOURIER
     
  • CANTOS - Residual Inflammatory Risk and Residual Cholesterol Risk: Critical Analysis from the CANTOS Trial
     

LBS.03. Latest Insights into Hypertension Management

When: Monday, November 13, 2017, 10:45 a.m. - 12:00 noon
Where: Main Event I (Hall D, Main Building)

  • Chinese BP Trial - Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality
     
  • SPRINT - Blood Pressure Measurement in the Systolic Blood Pressure Intervention Trial (SPRINT)
     
  • GATEWAY - Effects of Bariatric Surgery in Obese Patients with Hypertension
     

LBS.04. Sweet Spot in Cardiometabolic Care

When: Monday, November 13, 2017, 3:45 p.m. - 5:00 p.m.
Where: Ballroom CD, 3rd Level (Main Building)

  • CANVAS - Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results from the CANVAS Program
     
  • EXSCEL - Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial
     
  • EMPA-REG OUTCOME - Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
     
  • BiomarCaRE - Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population - The Biomarcare Consortium
     

LBS.05. New Insights into the Risks, Benefits, and Costs of Antithrombotic Therapy

When: Tuesday, November 14, 2017, 10:45 a.m. - 12:00 noon
Where: Main Event I (Hall D, Main Building)

  • COMPASS - Costs Impact Rivaroxaban Plus Aspirin Versus Aspirin in the COMPASS Trial
     
  • RE-DUAL PCI - Subgroup Analysis from the RE-DUAL PCI Trial: Dual Antithrombotic Therapy with Dabigatran in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
     
  • POISE-2 PCI Substudy - Aspirin in Patients with Previous Percutaneous Coronary Intervention (PCI) Undergoing Noncardiac Surgery
     
  • PRAGUE-18 - One-year Outcomes of Patients with Acute Myocardial Infarction Treated with Primary Angioplasty and Randomized to Prasugrel versus Ticagrelor - The Prague-18 Trial
     
  • GEMINI-ACS-1 - P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
     

LBS.06. Evaluating Quality Improvement and Patient Centered Care Interventions

When: Tuesday, November 14, 2017, 3:45 p.m. - 5:00 p.m.
Where: Ballroom CD, 3rd Level (Main Building)

  • SWEDEHEART registry results 1995-2014 - Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction During 20 years are Related to Implementation of Evidence-Based Treatments
     
  • STIC2IT - Results of the Study of a Tele-pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC2IT)
     
  • ACS QUIK - Effect of a Quality Improvement Toolkit on Acute Myocardial Infarction in India: The ACS QUIK Cluster Randomized, Stepped Wedge Trial
     
  • NZ STEP WEDGE - National Implementation Of A Clinical Guidance Framework for the Emergency Department Assessment of Patients with Possible Acute Coronary Syndromes
     
  • DECIDE-LVAD - Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure: the DECIDE-LVAD Trial
     

LBS.07. Innovative Therapies and Novel Applications

When: Wednesday, November 15, 2017, 9:00 a.m. - 10:15 a.m.
Where: Ballroom CD, 3rd Level (Main Building)

  • REDUCE LAP-HF - Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results from the REDUCE LAP-HF I Randomized Controlled Trial
     
  • TNT-POAF - Temporary Neurotoxin Treatment to Prevent Postoperative Atrial Fibrillation
     
  • PROPEL - Granulocyte Macrophage Colony-Stimulating Factor with and without Supervised Exercise to Improve Walking Performance in Peripheral Artery Disease
     
  • ALLSTAR - 6-Month Results of ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: A Randomized, placebo-controlled, double-blind study
     
  • HOPE-Duchenne - Cardiosphere-derived cells for the Treatment of Duchenne Cardiomyopathy: Results of the Halt cardiOmyopathy ProgrEssion [HOPE]-Duchenne Trial